PROVETOP

Biotinylated Human Kallikrein 7/KLK7 Protein (active form) (Primary Amine Labeling)

Catalog No: KLK7-HB001

Species
Human
Expression System
HEK293
Tag
Biotin
Activity
Activity verified

Product overview

Recombinant Biotinylated Human Kallikrein 7/KLK7 Protein (active form) (Primary Amine Labeling) is expressed in HEK293 cells without tag. It contains amino acid residues Ile30-Arg253 (UniProt accession: P49862-1).

Product Details

Molecular Aliases
Kallikrein-7; hK7; Serine protease 6; hSCCE; KLK7; PRSS6; SCCE
Protein Length
Ile30-Arg253
Expression System
HEK293
Theoretical Molecular Weight
The protein has a predicted MW of 24.44 kDa. Due to glycosylation, the protein migrates to 25-35 kDa based on Bis-Tris PAGE result.
Purity
> 95% as determined by Bis-Tris PAGE
Endotoxin
Less than 0.1 EU per μg by the LAL method.
Buffer / Formulation
Lyophilized from 0.22 μm filtered solution in 20mM HEPES, 150mM NaCl, 8% trehalose, 0.05% Brij-35, 5mM Benzamidine (pH 7.5).
State
Lyophilized
Storage Conditions
-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Reconstitution Advice
Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.

Data Display

Bis-Tris PAGE
KLK7-HB001 Bis-Tris-PAGE-white result

Biotinylated Human Kallikrein 7 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

ELISA
KLK7-HB001 ELISA result

Immobilized Biotinylated Human Kallikrein 7, No Tag at 0.5μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Anti-Kallikrein 7 Antibody, hFc Tag with the EC50 of 3.3ng/ml determined by ELISA. (QC Test)

Background

Kallikrein 7 (KLK7) is a secreted serine protease with chymotrypsic protease activity. Abnormally high expression of KLK7 is closely related to the occurrence and development of various types of cancer. Therefore, KLK7 has been identified as a potential target for cancer drug development design in recent years. KLK7 mediates various biological and pathological processes in tumorigenesis, including cell proliferation, migration, invasion, angiogenesis, and cell metabolism, by hydrolyzing a series of substrates such as membrane proteins, extracellular matrix proteins, and cytokines.

References

  1. Xiang F, Wang Y, Cao C, Li Q, Deng H, Zheng J, Liu X, Tan X. The Role of Kallikrein 7 in Tumorigenesis. Curr Med Chem. 2022;29(15):2617-2631. doi: 10.2174/0929867328666210915104537. PMID: 34525904.

Have questions about this product?

Our technical team can help with product selection, application questions and order support.

Contact Technical Support